Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06067555
Other study ID # 2000035891
Secondary ID 2T32AR007016-47
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date January 24, 2024
Est. completion date May 2026

Study information

Verified date February 2024
Source Yale University
Contact Andrew Johnston, MD, PhD
Phone 203-889-6634
Email Andrew.d.johnston@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after vaccination. The primary objective is to identify baseline correlates of immune response in the skin and peripheral blood to the seasonal influenza vaccine. The investigators secondary goals are to describe the inflammatory response in the skin over time.


Description:

Subjects will remain on study and may optionally repeat study visits (including vaccination) annually through the 2025-26 influenza season, with final study follow-up up to 1 year after vaccination. Sampling individual subjects across several influenza seasons will allow for monitoring of multi-season responses. Skin, blood, nasal mucosal lining fluid, and skin microbe samples will be collected at various timepoints before and up to 365 days after vaccination to explore short and long-term effects of immunization. Subjects may optionally provide stool samples.


Recruitment information / eligibility

Status Recruiting
Enrollment 249
Est. completion date May 2026
Est. primary completion date May 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study, as well as have deidentified samples and data stored for future research. 3. Able to proficiently speak, read, and write English. 4. Male or female, aged 18-40 years old at time of initial enrollment a. Participant is allowed to participate in subsequent influenza seasons even if they will be >40 years old. 5. In good general health as evidenced by medical history Individuals meeting any of the following criteria will be excluded from study participation: 1. CBC with differential, lymphocyte phenotyping with T, B, and natural killer cells (TBNK), complete metabolic panel, anti-CMV immunoglobulin (Ig) G and IgM, and/or anti-Epstein-Barr virus (EBV) antibody panel values outside of the Yale Department of Laboratory Medicine normal reference ranges and deemed clinically significant by the PI at the time of screening. 2. Positive result for anti-HIV 1/2 antibody screening at the time of screening. 3. Prior receipt of a current seasonal influenza vaccine (for the season of participation). 4. History of allergy or hypersensitivity to any components of the study vaccine (e.g., egg protein). 5. History of severe reactions to vaccines. 6. Use of an oral glucocorticoid within the past 30 days. 7. Receipt of a live-attenuated vaccine within the past 3 months. 8. Receipt of any experimental vaccine. 9. Receipt of any other type of vaccine (non-live and non-experimental, e.g., tetanus, diphtheria, and pertussis [TDaP]) within the past 3 months. 10. Planned vaccination before day 100 after study vaccination. 11. Current or recent use (within the past 90 days) of immunoglobulin therapy. 12. Surgery within the past 8 weeks, or planned surgery before day 28. 13. Current (within the past 30 days) treatment for active malignancy. 14. Cancer chemotherapy in the past 2 years. 15. Administration of any blood products within 90 days of the screening, or planned administration before day 100. 16. History of parasitic, amebic, fungal, or mycobacterial infections within the past 1 year, with the exception of tinea pedis and onychomycosis. 17. History of autoimmune or autoinflammatory disease. a. In particular skin-related (i.e. psoriasis, lichen planus, lupus, neutrophilic dermatoses, atopic dermatitis) 18. History of keloids 19. History of a bleeding disorder. 20. Current use (within the past 30 days) of illicit drugs (per subject report), with the exception of marijuana. 21. Current alcohol use disorders (criteria per Diagnostic and Statistical Manual of Mental Disorders, fifth edition), within the past 30 days. 22. Serious, ongoing, uncontrolled infection within the past 30 days as per the judgement of the PI. 23. History of Guillain-Barre syndrome (GBS). 24. BMI = 30. 25. Known or suspected immunodeficiency within 1 year, including documented HIV infection. 26. Pregnancy or planning to become pregnant during the study period. (Women of childbearing potential must have a negative urine or serum pregnancy test at screening.) 27. Presence of conditions that, in the judgment of the PI, may put the individual at undue risk or compromise the scientific objectives of the study. Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the PI. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the PI.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MicronJet
MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
Biological:
Fluzone® Quadrivalent
Intradermal injections of 0.3mL
Fluzone® Quadrivalent
Intramuscular injection of 0.3mL
Other:
Bacteriostatic Saline
Intradermal injection of 0.3mL (control)

Locations

Country Name City State
United States Church Street Research Unit New Haven Connecticut

Sponsors (5)

Lead Sponsor Collaborator
Yale University Chan Zuckerberg Initiative, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Silicon Valley Community Foundation, University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in antibody titer concentration to vaccination-Blood Change in antibody titer to vaccination as measured by microneutralization titers at day 0 and day 28 will be correlated with biomarkers in the blood using generalized estimating equations. Day 0 and Day 28
Primary Change in antibody titer concentration to vaccination-Skin Change in antibody titer to vaccination as measured by microneutralization titers at day 0 and day 28 will be correlated with biomarkers in the skin at baseline using generalized estimating equations. Day 0 and Day 28
Secondary Change in antibody titer concentration to vaccination Change in antibody titer response to vaccination as measured by microneutralization titers at day 0 and day 28 and its relationship with established baseline biomarkers (CD38+, CD20+, B cell, among others) and post-vaccination biomarkers (plasmablast, among others) in the blood will be correlated using generalized estimating equations. Day 0 and Day 28
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06091410 - Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines Phase 4
Completed NCT05057910 - SARS-CoV-2 (Covid-19) RBD Antibody in My Duc Hospital Healthcare Workers
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Recruiting NCT05028257 - Allergy and COVID-19 Vaccines Phase 3
Active, not recruiting NCT06286488 - Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza Phase 4
Recruiting NCT05546502 - Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Phase 3
Completed NCT05869201 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Phase 2/Phase 3
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Recruiting NCT05598372 - Infant Pain During Vaccination and Maternal Anxiety N/A
Active, not recruiting NCT06002503 - Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection Phase 1
Completed NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Completed NCT03400878 - Comparing Morbidity and Mortality Effects of Two Different Strains of BCG Phase 4
Completed NCT05069714 - One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. Phase 3
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Completed NCT04576910 - Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China Phase 4
Not yet recruiting NCT05094635 - Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts
Recruiting NCT05493917 - A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
Not yet recruiting NCT05171946 - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults Phase 1
Completed NCT05154383 - Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression Phase 4